Sacituzumab Govitecan: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40265-020-01337-5.pdf
Reference45 articles.
1. Immunomedics. Advanced antibody-based therapeutics [presentation]. 2017. https://www.immunomedics.com. Accessed 20 May 2020.
2. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (Trop-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–9006.
3. Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496–512.
4. Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjugate Chem. 2015;26(5):919–31.
5. Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer-xenograft models and monkeys. Clin Cancer Res. 2011;2011:clincanres.2939.010.
Cited by 171 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release;European Journal of Medicinal Chemistry;2024-10
2. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10
3. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions;Pharmacological Research;2024-09
4. On the shoulder of ADC: The development of 124I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imaging;Biomedicine & Pharmacotherapy;2024-09
5. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3